Cholesterol and 24S-hydroxycholesterol trafficking in Alzheimer’s disease

References

• Pfrieger FW. Cholesterol homeostasis and function in neurons of the central nervous system. Cell. Mol. Life Sci.60, 1158–1171 (2003).
   PubMed Web of Science ®Google Scholar
• Lukiw WJ, Pappolla M, Pelaez RP, Bazan NG. Alzheimer's disease – a dysfunction in cholesterol and lipid metabolism. Cell Mol. Neurobiol.25, 475–483 (2005).
   PubMed Web of Science ®Google Scholar
• Shobab LA, Hsiung GY, Feldman HH. Cholesterol in Alzheimer's disease. Lancet Neurol.4, 841–852 (2005).
   PubMed Web of Science ®Google Scholar
• Alexandrov P, Cui JG, Zhao Y, Lukiw WJ. 24S-hydroxycholesterol induces inflammatory gene expression in primary human neural cells. Neuroreport.16, 909–913 (2005).
   PubMedGoogle Scholar
• Flirski M, Sobow T. Biochemical markers and risk factors of Alzheimer's disease. Curr. Alzheimer Res.2, 47–64 (2005).
   PubMedGoogle Scholar
• Grant WB. Dietary links to Alzheimer’s Disease. J. Alz. Dis.1, 197–201 (1999).
   PubMedGoogle Scholar
• Miller LJ, Chacko R. The role of cholesterol and statins in Alzheimer's disease. Ann. Pharmacother.38, 91–98 (2004).
   PubMed Web of Science ®Google Scholar
• Pappolla MA, Bryant-Thomas TK, Herbert D et al. Hypercholesterolemia is an early risk factor for the development of alzheimer amyloid pathology. Neurology61, 199–205 (2003).
   PubMed Web of Science ®Google Scholar
• Refolo LM, Malester B, LaFrancois J et al. Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model. Neurobiol. Dis.7, 321–331 (2000).
   PubMed Web of Science ®Google Scholar
• Bjorkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol.24, 806–815 (2004).
   PubMed Web of Science ®Google Scholar
• Rebeck GW. Cholesterol efflux as a critical component of Alzheimer's disease pathogenesis. J. Mol. Neurosci.23, 219–224 (2004).
   PubMed Web of Science ®Google Scholar
• Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr. Opin. Lipidol.12, 105–112 (2001).
   PubMed Web of Science ®Google Scholar
• Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosc.5, 347–360 (2004).
   PubMed Web of Science ®Google Scholar
• Wolozin B. Cholesterol, statins and dementia. Curr. Opin. Lipidol.15, 667–672 (2004).
   PubMed Web of Science ®Google Scholar
• Levi O, Lutjohann D, Devir A, von Bergmann K, Hartmann T, Michaelson DM. Regulation of hippocampal cholesterol metabolism by apoE and environmental stimulation. J. Neurochem.95, 987–997 (2005).
   PubMedGoogle Scholar
• Petanceska SS, DeRosa S, Sharma A et al. Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol. J. Mol. Neurosci.20, 395–406 (2003).
   PubMed Web of Science ®Google Scholar
• Strittmatter WJ, Saunders AM, Schmeche D et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA.90, 1977–1981 (1993).
   PubMed Web of Science ®Google Scholar
• Aliev G, Smith MA, Obrenovich ME, de la Torre JC, Perry G. Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease. Neurotox. Res.5, 491–504 (2003).
   PubMed Web of Science ®Google Scholar
• Lahiri DK, Sambamurti K, Bennett DA. Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and eidemiological studies of Alzheimer's disease. Neurobiol. Aging25, 651–660 (2004).
   PubMedGoogle Scholar
• Cutler RG, Kelly J, Storie K et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl Acad. Sci. USA101, 2070–2075 (2004).
   PubMed Web of Science ®Google Scholar
• Pasternak SH, Callahan JW, Mahuran DJ. The role of the endosomal/ lysosomal system in amyloid-β production and the pathophysiology of Alzheimer's disease: re-examining the spatial paradox from a lysosomal perspective. J. Alzheimers Dis.6, 53–65 (2004).
   PubMed Web of Science ®Google Scholar
• Wood WG, Schroeder F, Avdulov NA, Chochina SV, Igbavboa U. Recent advances in brain cholesterol dynamics: transport, domains and Alzheimer’s disease. Lipids34, 225–234 (1999).
   PubMed Web of Science ®Google Scholar
• Ogura T, Mio K, Hayashi I et al. Three-dimensional structure of the γ-secretase complex. Biochem. Biophys. Res. Commun. (2006). [Epub ahead of print].
   Google Scholar
• Dunys J, Kawarai T, Wilk S et al. Catabolism of endogenous and overexpressed APH1a and PEN2: evidence for artifactual involvement of the proteasome in the degradation of overexpressed proteins. Biochem. J.394, 501–509 (2006).
   PubMedGoogle Scholar
• Bazan NG, Colangelo V, Lukiw WJ. Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins and Other Lipid Mediators68–69, 197–210 (2002).
   Google Scholar
• Kolsch H, Lutjohann D, Tulke A, Bjorkhem I, Rao ML. The neurotoxic effect of 24-hydroxycholesterol on SH-SY5Y human neuroblastoma cells. Brain Res.818, 171–175 (1999).
   PubMed Web of Science ®Google Scholar
• Bodovitz S, Klein WL. Cholesterol modulates α-secretase cleavage of amyloid precursor protein. J. Biol. Chem.271, 4436–4440 (1996).
   PubMed Web of Science ®Google Scholar
• Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM. The role of cholesterol in the biosynthesis of β-amyloid. Neuroreport.10, 1699–1705 (1999).
   PubMed Web of Science ®Google Scholar
• Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC. β-secretase activity increases with aging in human, monkey, and mouse brain. Am. J. Pathol.164, 719–725 (2004).
   PubMed Web of Science ®Google Scholar
• Gibson WW, Eckert GP, Igbavboa U, Muller WE. Amyloid β-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease. Biochim. Biophys. Acta.1610, 281–290 (2003).
   PubMed Web of Science ®Google Scholar
• Hoglund K, Wiklund O, Vanderstichel H, Eikenberg O, Vanmechelen E, Blennow K. Plasma levels of β-amyloid(1–40), β-amyloid(1–42), and total β-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch. Neurol.61, 333–337 (2004).
   PubMed Web of Science ®Google Scholar
• Jankowsky JL, Fadale DJ, Anderson J et al. Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase. Hum. Mol. Genet.13, 159–170 (2004).
   PubMed Web of Science ®Google Scholar
• Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: the cholesterol connection. Nat. Neurosci.6, 345–351 (2003).
   PubMed Web of Science ®Google Scholar
• Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Pro. Natl Acad. Sci. USA95, 6460–6464 (1998).
   PubMed Web of Science ®Google Scholar
• Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B. Clearance of amyloid β-peptide from brain: transport or metabolism? Nat. Med.6, 718 (2000).
   Web of Science ®Google Scholar
• Eckert GP, Kirsch C, Leutz S, Wood WG, Muller WE. Cholesterol modulates amyloid β-peptide's membrane interactions. Pharmacopsychiatry36, S136–S143 (2003).
   Google Scholar
• Sidera C, Parsons R, Austen B. Proteolytic cascade in the amyloidogenesis of Alzheimer's disease. Biochem. Soc. Trans.32, 33–36 (2004).
   PubMed Web of Science ®Google Scholar
• Qin W, Ho L, Pompl PN et al. Cyclooxygenase (COX)-2 and COX-1 potentiate β-amyloid peptide generation through mechanisms that involve γ-secretase activity. J. Biol. Chem.278, 50970–50977 (2003).
   PubMedGoogle Scholar
• Mizuno T, Haass C, Michikawa M, Yanagisawa K. Cholesterol-dependent generation of a unique amyloid β-protein from atypically missorted amyloid precursor protein in MDCK cells. Biochem. Biophys. Acta.1373, 119–130 (1998).
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Fernandez-Novoa L, Lombardi V, Corzo L, Pichel V, Kubota Y. Cerebrovascular risk factors in Alzheimer's disease: brain hemodynamics and pharmacogenomic implications. Neurol. Res.25, 567–580 (2003).
   PubMed Web of Science ®Google Scholar
• Papassotiropoulos A, Lutjohann D, Bagli M et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res.36, 27–32 (2002).
   PubMed Web of Science ®Google Scholar
• Papassotiropoulos A, Lutjohann D, Bagli M et al. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport11, 1959–1962 (2000).
   PubMed Web of Science ®Google Scholar
• Lutjohann D, von Bergmann K. 24S-hydroxycholesterol: a marker of brain cholesterol metabolism. Pharmacopsychiatry2, 102–106 (2003).
   Google Scholar
• Ohyama Y, Meaney S, Heverin M et al. Studies on the transcriptional regulation of cholesterol 24-hydroxylase(CYP46A1): marked insensitivity towards different regulatory axes. J. Biol. Chem.281(7), 3810–3820 (2005).
   PubMedGoogle Scholar
• Papassotiropoulos A, Wollmer MA, Tsolaki M et al. A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. J. Clin. Psych.66, 940–947 (2005).
   Google Scholar
• Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J. Neurosci. Res.70, 462–473 (2002).
   PubMed Web of Science ®Google Scholar
• Lukiw WJ, Cui JG, Marcheselli VL et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest.115, 2774–83 (2005).
   PubMed Web of Science ®Google Scholar
• Bazan NG, Lukiw WJ. Cyclooxygenase-2 and presenilin-1 gene expression induced by interleukin-1β and amyloid β 42 peptide is potentiated by hypoxia in primary human neural cells. J. Biol. Chem.277, 30359–30367 (2002).
   PubMedGoogle Scholar
• Lukiw WJ. Gene expression profiling in fetal, aged and Alzheimer hippocampus: a continuum of stress-related signaling. Neurochem. Res.29, 1287–1297 (2004).
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Boyd-Kimball D. Amyloid β-peptide(1–42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol.14, 426–432 (2004).
   PubMed Web of Science ®Google Scholar
• Kolsch H, Heun R, Kerksiek A, Bergmann KV, Maier W, Lutjohann D. Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. Neurosci Lett.368, 303–308 (2004).
   PubMed Web of Science ®Google Scholar
• Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol and misfolded proteins. Lancet363, 1139–1146 (2004).
   PubMed Web of Science ®Google Scholar
• Beasley CL, Honer WG, Bergmann K, Falkai P, Lutjohann D, Bayer TA. Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Disord.7, 449–455 (2005).
   PubMed Web of Science ®Google Scholar
• Baskin F, Rosenberg RN, Fang X et al. Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients. Neurology60, 2006–2007 (2003).
   PubMed Web of Science ®Google Scholar
• Edwards JE, Moore RA. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Family Pract.4, 18 (2003).
   PubMedGoogle Scholar
• Miida T, Takahashi A, Tanabe N, Ikeuchi T. Can statin therapy really reduce the risk of Alzheimer's disease and slow its progression? Curr. Opin. Lipidol.16, 619–623 (2005).
   PubMed Web of Science ®Google Scholar
• Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet.356, 1627–1631 (2000).
   PubMed Web of Science ®Google Scholar
• Launer L. Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer's disease: dissecting the epidemiological evidence. Drugs63, 731–739 (2003).
   PubMedGoogle Scholar
• Park IH, Hwang EM, Hong HS et al. Lovastatin enhances Aβ production and senile plaque deposition in female Tg2576 mice. Neurobiol. Aging24, 637–643 (2003).
   PubMed Web of Science ®Google Scholar
• Sparks DL, Martin TA, Gross DR, Hunsaker JC. III Link between heart disease, cholesterol, and Alzheimer's disease: a review. Microsc. Res. Tech.50, 287–290 (2000).
   PubMed Web of Science ®Google Scholar
• Stuve O, Youssef S, Steinman L, Zamvil SS. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr. Opin. Neurol.16, 393–401 (2003).
   PubMed Web of Science ®Google Scholar
• Weir MR, Sperling RS, Reicin A, Gert BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib program. Am. Heart J.146, 591–604 (2003).
   PubMed Web of Science ®Google Scholar
• Wilson HL, Schwartz DM, Bhatt HR, McCulloch CE, Duncan JL. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am. J. Ophthalmol.137, 615–624 (2004).
   PubMed Web of Science ®Google Scholar
• Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch. Neurol.57, 1439–1443 (2000).
   PubMed Web of Science ®Google Scholar
• Wolozin B. Cyp46 (24S-cholesterol hydroxylase): a genetic risk factor for Alzheimer disease. Arch. Neurol.60, 29–35 (2003).
   PubMedGoogle Scholar
• Hoglund K, Thelen KM, Syversen S et al. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord.19, 256–265 (2005).
   PubMed Web of Science ®Google Scholar
• Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev.56, 387–437 (2004).
   PubMed Web of Science ®Google Scholar
• Locatelli S, Lutjohann D, Schmidt HH, Otto C, Beisiegel U, von Bergmann K. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch. Neurol.59, 213–216 (2002).
   PubMed Web of Science ®Google Scholar
• Li G, Shofer JB, Kukull WA et al. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology65, 1045–1050 (2005).
   PubMed Web of Science ®Google Scholar
• Bi X, Baudry M, Liu J et al. Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia. J. Biol. Chem.279, 48238–48245 (2004).
   PubMedGoogle Scholar
• Golanska E, Hulas-Bigoszewska K, Wojcik I et al. CYP46: a risk factor for Alzheimer's disease or a coincidence? Neurosci Lett.383,105–108 (2005)
   PubMedGoogle Scholar
• Ingelsson M, Jesneck J, Irizarry MC, Hyman BT, Rebeck GW. Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer's disease. Neurosci. Lett.367, 228–231 (2004).
   PubMedGoogle Scholar
• Irizarry MC. Biomarkers of Alzheimer disease in plasma. NeuroRx.1, 226–234 (2004).
   PubMedGoogle Scholar
• Zatta P, Zambenedetti P, Stella MP, Licastro F. Astrocytosis, microgliosis, metallothionein-I-II and amyloid expression in high cholesterol-fed rabbits. J. Alzheimers Dis.4, 1–9 (2002).
   PubMedGoogle Scholar
• Blain JF, Paradis E, Gaudreault SB, Champagne D, Richard D, Poirier J. A role for lipoprotein lipase during synaptic remodeling in the adult mouse brain. Neurobiol Dis.15, 510–519 (2004).
   PubMedGoogle Scholar
• Ravona-Springer R, Davidson M, Noy S. The role of cardiovascular risk factors in Alzheimer's disease. CNS Spectr.8, 824–833 (2003).
   PubMedGoogle Scholar
• Bassett CN, Montine TJ. Lipoproteins and lipid peroxidation in Alzheimer's disease. J. Nutr. Health Aging.7, 24–9 (2003).
   PubMedGoogle Scholar
• Mirra SS, Heyman A, McKeel D et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology41, 479–486 (1991).
   PubMed Web of Science ®Google Scholar
• Schenk D. Alzheimer's disease: a partner for presenilin. Nature407, 48–54 (2000).
   PubMedGoogle Scholar
• Murphy MP, Das P, Nyborg AC et al. Overexpression of nicastrin increases Aβ production. FASEJ.17, 1138–1140 (2003).
   PubMedGoogle Scholar
• Marcheselli VL, Hong S, Lukiw WJ et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem.278, 43807–43817 (2003).
   PubMed Web of Science ®Google Scholar
• Finch CE. Developmental origins of aging in brain and blood vessels: an overview. Neurobiol. Aging26, 281–291 (2005).
   PubMedGoogle Scholar
• Mullenix PS, Andersen CA, Starnes BW. Atherosclerosis as inflammation. Ann. Vasc. Surg.19, 130–138 (2005).
   PubMed Web of Science ®Google Scholar
• Sun GY, Xu J, Jensen MD, Simonyi A. Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J. Lipid Res.45, 205–213 (2004).
   PubMed Web of Science ®Google Scholar
• Handschin C, Meyer UA. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR and FXR. Arch. Biochem. Biophys.433, 387–396 (2005).
   PubMed Web of Science ®Google Scholar
• Lutjohann D, Bjorkhem I, Locatelli S et al. Cholesterol dynamics in the foetal and neonatal brain as reflected by circulatory levels of 24S-hydroxycholesterol. Acta Paediatr.90, 652–657 (2001).
   PubMedGoogle Scholar
• Yoo BC, Seidl R, Cairns N, Lubec G. Heat-shock protein 70 levels in brain of patients with Down syndrome and Alzheimer's disease. J. Neural. Transm. Suppl.57, 315–322 (1999).
   PubMedGoogle Scholar
• Flood DG, Reaume AG, Dorfman KS et al. Mutant PS-1 gene-targeted mice: increased Aβ42 and Aβ deposition without APP overproduction. Neurobiol. Aging23, 335–348 (2002).
   PubMedGoogle Scholar
• Alexandrov PN, Zhao Y, Pogue AI et al. Synergistic effects of iron and aluminum on stress-related gene expression in primary human neural cells. J. Alzheimers Dis.8, 117–127 (2005).
   PubMedGoogle Scholar
• Boedker M, Boetkjaer A, Bazan NGet al. Budesonide epimer R, LAU-8080 and phenyl butyl nitrone synergistically repress cyclooxygenase-2 induction in [IL-1β+Aβ42]-stressed human neural cells. Neurosci Lett.380, 176–180 (2005).
   PubMedGoogle Scholar
• Xu C, Li CY, Kong AN. Induction of Phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res.28, 249–268 (2005).
   PubMed Web of Science ®Google Scholar
• Mohan R, Heyman RA. Orphan nuclear receptor modulators. Curr. Top. Med. Chem.3, 1637–1647 (2003).
   PubMed Web of Science ®Google Scholar
• Shechter M, Beigel R, Matetzky S, Freimark D, Chouraqui P. The intensive statin therapy myth. Israeli Med. Assoc. J.7, 683–687 (2005).
   PubMedGoogle Scholar
• Sparks DL, Sabbagh MN, Connor DJ et al. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr. Alzheimer Res.2, 343–353 (2005).
   PubMedGoogle Scholar
• Mora S, Ridker PM. Justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin (JUPITER)–can C-reactive protein be used to target statin therapy in primary prevention? Am. J. Cardiol.97, 33–41 (2006).
   PubMed Web of Science ®Google Scholar
• Miyazaki A, Kanome T, Watanabe T.Inhibitors of acyl-coenzyme a: cholesterol acyltransferase. Curr. Drug Targets Cardiovasc. Haematol. Disord.5, 463–469 (2005).
   PubMedGoogle Scholar
• Brown WJ, Schmidt JA. Use of acyltransferase inhibitors to block vesicular traffic between the ER and golgi complex. Methods Enzymol.404, 115–125 (2005).
   PubMed Web of Science ®Google Scholar
• Burnett JR, Telford DE, Barrett PH, Huff MW. The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. Biochim. Biophys. Acta.1738, 10–18 (2005).
   PubMed Web of Science ®Google Scholar
• Yatskar L, Fisher EA, Schwartzbard A. Ezetimibe:rationale and role in the management of hypercholesterolemia. Clin. Cardiol.29, 52–55 (2006).
   PubMed Web of Science ®Google Scholar
• Chaki O. Next generation selective estrogen receptor modulators. Clin. Calcium.16, 145–152 (2006).
   PubMedGoogle Scholar
• Rodenburg J, Vissers MN, Daniels SR, Wiegman A, Kastelein JJ. Lipid-lowering medications. Pediatr. Endocrinol. Rev.2(Suppl. 1) 171–180 (2004).
   PubMedGoogle Scholar
• Denke MA. Diet, lifestyle, and nonstatin trials: review of time to benefit. Am. J. Cardiol.96, 3F–10F (2005).
   PubMed Web of Science ®Google Scholar
• Schmitt B, Bernhardt T, Moeller HJ, Heuser I, Frolich L. Combination therapy in Alzheimer's disease: a review of current evidence. CNS Drugs.18, 827–844 (2004).
   PubMed Web of Science ®Google Scholar